Mirna Therapeutics researches on and develops miRNA-directed human oncology therapies.
Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biopharmaceutical research and development company focused on miRNA-directed human oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and an expansive IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 5, 2015 | Post-IPO Equity | $16.80M | — | — | — | Detail |
| Sep 30, 2015 | IPO | $44M | — | — | — | Detail |
| Apr 30, 2015 | Series D | $41.80M | 11 |
Baxter Ventures
|
— | Detail |
| Oct 24, 2012 | Series C | $34.50M | 6 |
Sofinnova Investments
|
— | Detail |
| Aug 23, 2011 | Series B | $1.50M | — | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Baxter Ventures
|
Yes | Series D |
Celgene
|
— | Series D |
Correlation Ventures
|
— | Series D |
Eastern Capital
|
— | Series D |
Morningside Group
|
— | Series D |
New Enterprise Associates
|
— | Series D |
|
|
— | Series D |
Pfizer Venture Investments
|
— | Series D |
|
|
— | Series D |
Sante Ventures
|
— | Series D |